A peek at Emergent Biosolutions Inc (EBS): Who has invested in It?

Emergent Biosolutions Inc (NYSE: EBS) is -30.00% lower on its value in year-to-date trading and has touched a low of $1.42 and a high of $16.66 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EBS stock was last observed hovering at around $1.50 in the last trading session, with the day’s gains setting it 0.18%.

Currently trading at $1.68, the stock is -8.02% and -20.99% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.24 million and changing 12.00% at the moment leaves the stock -65.20% off its SMA200. EBS registered -88.09% loss for a year compared to 6-month loss of -71.62%. The firm has a 50-day simple moving average (SMA 50) of $0.80 and a 200-day simple moving average (SMA200) of -$1.62.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


Sponsored

The stock witnessed a -19.23% gain in the last 1 month and extending the period to 3 months gives it a -28.81%, and is 1.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.57% over the week and 7.92% over the month.

Emergent Biosolutions Inc (EBS) has around 2500 employees, a market worth around $87.16M and $1.10B in sales. Fwd P/E is 1.09. Profit margin for the company is -72.06%. Distance from 52-week low is 18.31% and -89.92% from its 52-week high. The company has generated returns on investments over the last 12 months (-68.59%).

Emergent Biosolutions Inc quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $293.53M over the same period.The EPS is expected to shrink by -117.08% this year, but quarterly earnings will post -4.80% year-over-year. Quarterly sales are estimated to shrink -11.20% in year-over-year returns.

218 institutions hold shares in Emergent Biosolutions Inc (EBS), with institutional investors hold 84.41% of the company’s shares. The shares outstanding are 50.10M, and float is at 49.75M with Short Float at 23.75%. Institutions hold 82.28% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 9.23 million shares valued at $67.85 million. The investor’s holdings represent 17.82% of the EBS Shares outstanding. As of Jun 29, 2023, the second largest holder is State Street Corporation with 6.79 million shares valued at $49.94 million to account for 13.11% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 4.34 million shares representing 8.38% and valued at over $31.92 million, while Dimensional Fund Advisors LP holds 2.88% of the shares totaling 1.49 million with a market value of $10.95 million.

Emergent Biosolutions Inc (EBS) Insider Activity

A total of 5 insider transactions have happened at Emergent Biosolutions Inc (EBS) in the last six months, with sales accounting for 3 and purchases happening 2 times. The most recent transaction is an insider sale by Zoon Kathryn C, the company’s Director. SEC filings show that Zoon Kathryn C sold 1,830 shares of the company’s common stock on Jun 02 at a price of $8.35 per share for a total of $15280.0. Following the sale, the insider now owns 49971.0 shares.

Emergent Biosolutions Inc disclosed in a document filed with the SEC on May 25 that Zoon Kathryn C (Director) sold a total of 1,700 shares of the company’s common stock. The trade occurred on May 25 and was made at $8.38 per share for $14246.0. Following the transaction, the insider now directly holds 51801.0 shares of the EBS stock.

Emergent Biosolutions Inc (EBS): Who are the competitors?

One of the company’s main competitors (and peers) include SIGA Technologies Inc. (SIGA) that is trading -31.66% down over the past 12 months.Pfizer Inc. (PFE) lies in the list of competitors of the Emergent Biosolutions Inc and is -37.17% lower over the same period from EBSSoligenix Inc. (SNGX) is -87.89% down on the 1-year trading charts.